HIGH PERFORMANCE ANTIBODIES … AND MORE

Infectious Disease

    Primary Antibodies

  • ACE2 Antibody

    Catalog Number: 3215

    Clonality: Polyclonal

    Tested Applications: ELISA, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    9 Image(s)

    • <strong>Figure 1 Independent Antibody Validation (IAV) via Protein Expression Profile in Human Tissues</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3215 (2 μg/mL), ACE2, 3217 (2 μg/mL), ACE2, 3227 (2 μg/mL) and beta-actin 3779 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 2 Western Blot Validation in Human Tissues</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3215 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 3 Western Blot Validation in Mouse Tissues</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3215 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 4 Western Blot Validation in Rat Skin Tissue</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3215 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 5 Immunohistochemistry Validation of ACE2 in Human Kidney Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-ACE2 antibody (3215) at 2 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
    • <strong>Figure 6 Immunofluorescence Validation of ACE2 in Human Testis Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human testis tissue labeling ACE-2 with 3215 at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 7 Immunofluorescence Validation of ACE2 in Human Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human lung tissue labeling ACE-2 with 3215 at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 8 Immunofluorescence Validation of ACE2 in Rat Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed rat lung tissue labeling ACE-2 with 3215 at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 9 Immunofluorescence Validation of ACE2 In Caco2 Cells </strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed Caco2 cells labeling ACE2 with 3215 at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue). Image showing membrane staining on Caco2 cells.

  • ACE2 Antibody

    Catalog Number: 3217

    Clonality: Polyclonal

    Tested Applications: ELISA, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    11 Image(s)

    • <strong>Figure 1 Independent Antibody Validation (IAV) via Protein Expression Profile in Human Tissues</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3215 (2 μg/mL), ACE2, 3217 (2 μg/mL), ACE2, 3217 (2 μg/mL) and beta-actin 3779 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 2 Western Blot Validation in Human Tissues and Cell Line</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3217 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 3 Western Blot Validation in Mouse Tissues </strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3217 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 4 Western Blot Validation in Rat Tissues </strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3217 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 5 Immunofluorescence Validation of ACE2 in Human Testis Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human testis tissue labeling ACE-2 with 3217 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 6 Immunofluorescence Validation of ACE2 in Human Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human lung tissue labeling ACE-2 with 3217 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 7 Immunofluorescence Validation of ACE2 in Mouse Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse lung tissue labeling ACE-2 with 3217 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 8 Immunofluorescence Validation of ACE2 in Rat Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed rat lung tissue labeling ACE-2 with 3217 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 9 Immunohistochemistry Validation of ACE2 in Human Kidney Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-ACE2 antibody (3217) at 2 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
    • <strong>Figure 10 Immunofluorescence Validation of ACE2 in Human Kidney Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human kidney cells labeling ACE2 with 3217 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).
    • <strong>Figure 11 Immunofluorescence Validation of ACE2 In Caco2 Cells </strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed Caco2 cells labeling ACE2 with 3217 at 5 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue). Image showing membrane staining on Caco2 cells.

  • ACE2 Antibody

    Catalog Number: 3227

    Clonality: Polyclonal

    Tested Applications: ELISA, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    11 Image(s)

    • <strong>Figure 1 Independent Antibody Validation (IAV) via Protein Expression Profile in Human Tissues</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3215 (2 μg/mL), ACE2, 3217 (2 μg/mL), ACE2, 3227 (2 μg/mL) and beta-actin 3779 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 2 Western Blot Validation in Human Tissues</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3227 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 3 Western Blot Validation in Mouse Tissues</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3227 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 4 Western Blot Validation in Rat Thymus Tissue</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3227 (2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 5 Immunohistochemistry Validation of ACE2 in Human Kidney Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-ACE2 antibody (3227) at 2 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 ˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
    • <strong>Figure 6 Immunofluorescence Validation of ACE2 in Human Testis Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human testis tissue labeling ACE-2 with 3227 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 7 Immunofluorescence Validation of ACE2 in Human Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human lung tissue labeling ACE-2 with 3227 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 8 Immunofluorescence Validation of ACE2 in Mouse Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse lung tissue labeling ACE-2 with 3227 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 9 Immunofluorescence Validation of ACE2 in Rat Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed rat lung tissue labeling ACE-2 with 3227 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 10 Immunofluorescence Validation of ACE2 in Human Kidney Cells</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human kidney cells labeling ACE2 with 3227 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).
    • <strong>Figure 11 Immunofluorescence Validation of ACE2 In Caco2 Cells </strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed Caco2 cells labeling ACE2 with 3227 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue). Image showing membrane staining on Caco2 cells.

  • ACE2 Antibody

    Catalog Number: 3229

    Clonality: Polyclonal

    Tested Applications: ELISA, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    10 Image(s)

    • <strong>Figure 1 Western Blot Validation in Human Tissues</strong><br> Loading: 15 µg of lysates per lane. Antibodies: ACE2, 3229 (4 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 2 Western Blot Validation in Mouse Stomach Tissue</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3229 (4 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 3 Western Blot Validation in Rat Brain Tissue</strong><br> Loading: 15 μg of lysates per lane. Antibodies: ACE2, 3229 (4 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 4 Immunohistochemistry Validation of ACE2 in Human Kidney Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-ACE2 antibody (3229) at 2 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 ˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
    • <strong>Figure 5 Immunofluorescence Validation of ACE2 in Human Kidney Cells</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human kidney cells labeling ACE2 with 3229 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green).
    • <strong>Figure 6 Immunofluorescence Validation of ACE2 in Human Testis Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human testis tissue labeling ACE-2 with 3229 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 7 Immunofluorescence Validation of ACE2 in Human Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human lung tissue labeling ACE-2 with 3229 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 8 Immunofluorescence Validation of ACE2 in Mouse Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse lung tissue labeling ACE-2 with 3229 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 9 Immunofluorescence Validation of ACE2 in Rat Lung Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed rat lung tissue labeling ACE-2 with 3229 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 10 Immunofluorescence Validation of ACE2 In Caco2 Cells </strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed Caco2 cells labeling ACE2 with 3229 at 5 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue). Image showing membrane staining on Caco2 cells.

  • ATR Antibody

    Catalog Number: 3117

    Clonality: Polyclonal

    Tested Applications: ELISA, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    3 Image(s)

    • Western blot analysis of ATR in HepG2 cell lysates with ATR antibody (IN) at (A) 0.5, (B) 1, and (C) 2 μg/mL.
    • Immunohistochemical staining of human brain tissue using ATR antibody at 2 μg/mL.
    • Immunofluorescence of ATR in Human Brain tissue with ATR antibody at 10 ug/mL.

  • CAPN6 Antibody

    Catalog Number: 4759

    Clonality: Polyclonal

    Tested Applications: ELISA, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    3 Image(s)

    • Western blot analysis of CAPN6 in rat lung tissue lysate with CAPN6 antibody at (A) 0.5 and (B) 1 μg/mL.
    • Immunohistochemistry of CAPN6 in human lung tissue with CAPN6 antibody at 2.5 μg/mL.
    • Immunofluorescence of CAPN6 in Human Lung cells with CAPN6 antibody at 20 μg/mL.

  • CCR3 Antibody

    Catalog Number: 1105

    Clonality: Polyclonal

    Tested Applications: ELISA, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    3 Image(s)

    • Western blot analysis of CCR3 in human spleen tissue lysates with CCR3 antibody at 1 (lane 1) and 2 μg/mL (lane 2), and 2 μg/mL in the presence of blocking peptide (lane 3).
    • Immunohistochemistry of CCR3 in human spleen tissue with CCR3 antibody at 10 μg/mL.
    • Immunofluorescence of CCR3 in Human Spleen tissue with CCR3 antibody at 20 μg/mL.

  • CD81 Antibody

    Catalog Number: 5195

    Clonality: Polyclonal

    Tested Applications: ELISA, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    5 Image(s)

    • Western blot analysis of CD81 in human lung tissue lysate with CD81 antibody at 1 μg/mL in (A) the absence and (B) the presence of blocking petide.
    • Immunohistochemistry of CD81 in human lung tissue with CD81 antibody at 5 μg/mL.
    • Immunofluorescence of CD81 in A549 cells with CD81 antibody at 20 μg/mL.
    • Immunohistochemistry of CD81 in human brain tissue with CD81 antibody at 2 μg/ml.
    • Immunofluorescence of CD81 in human brain tissue with CD81 antibody at 10 μg/ml.<br><br>Green: CD81 Antibody (5195) <br> Blue: DAPI staining

  • CD81 Antibody [1.3.3.22]

    Catalog Number: 33-829

    Clonality: Monoclonal

    Tested Applications: Flow, Func, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Mouse

    Conjugate: Unconjugated

    Size: 100 ug

    2 Image(s)

    • IHC testing of FFPE human lymph node with CD81 antibody (clone 1.3.3.22). Required HIER: boil tissue sections in 10mM citrate buffer, pH 6, for 10-20 min followed by cooling at RT for 20 min.
    • IHC testing of FFPE human tonsil with CD81 antibody (clone 1.3.3.22). Required HIER: boil tissue sections in 10mM citrate buffer, pH 6, for 10-20 min followed by cooling at RT for 20 min.

  • CX3CR1 Antibody

    Catalog Number: 2093

    Clonality: Polyclonal

    Tested Applications: ELISA, Flow, IF, IHC-P, WB

    Species Reactivity: Human, Mouse, Rat

    Host Species: Rabbit

    Conjugate: Unconjugated

    Size: 0.02 mg, 0.1 mg

    15 Image(s)

    • <strong>Figure 1 Western Blot Validation in Human Cells </strong><br> Loading: 15 μg of lysates per lane. Antibodies: CX3CR1 2093 (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 2 KD Validation in 293 Cells</strong><br> Loading: 15 μg of lysates per lane. Antibodies: CX3CR1 2093 (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 293 cells transfected with control siRNAs. Lane 2: 293 cells transfected with CX3CR1 siRNAs.
    • <strong>Figure 3 Western Blot Validation in THP1 Cells </strong><br> Loading: 15 μg of lysates per lane. Antibodies: CX3CR1 2093 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 0.2 μg/mL Lane 1: 0.5 μg/mL Lane 1: 1 μg/mL
    • <strong>Figure 4 Western Blot Validation in Human Spleen Lysates</strong><br> Loading: 15 μg of lysates per lane. Antibodies: CX3CR1 2093 (1 μg/mL) in the absence (lane 1) or presence of blocking peptide (lane 2), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 5 Western Blot Validation in Rat Spleen Tissue</strong><br> Loading: 15 μg of lysates per lane. Antibodies: CX3CR1 2093, (A; 1 μg/mL, B; 2 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
    • <strong>Figure 6 Flow Cytometry Validation of CX3CR1 in THP-1 Cells</strong><br> Overlay histogram showing THP-1 cells stained with 2093 (red line, 1μg/1x10<sup>6</sup> cells). 1 h incubation at 4˚C in 2% FBS/PBS. Followed by secondary antibody 488 goat anti-rabbit IgG (H+L) at 1/500 dilution for 1 h 4˚C. <br> <br> Isotype control antibody (Green line) was rabbit IgG1 (1μg/1x10<sup>6</sup> cells) used under the same conditions. Acquisition of >10,000 events was performed.
    • <strong>Figure 7 Immunofluorescence Validation of CX3CR1 In K562 Cells </strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed K562 cells labeling CX3CR1 with 2093 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue). Image showing membrane staining on K562 cells.
    • <strong>Figure 8 Immunofluorescence Validation of CX3CR1 in Human Heart </strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed human heart tissue labeling CX3CR1 with 2093 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).
    • <strong>Figure 9 Immunofluorescence Validation of CX3CR1 in Mouse Heart Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse heart tissue labeling CX3CR1 with 2093 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 10 Immunohistochemistry Validation of CX3CR1 in Rat Heart Tissue </strong><br> Immunohistochemical analysis of paraffin-embedded rat heart tissue using anti-CX3CR1 antibody (2093) at 2 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
    • <strong>Figure 11 Immunofluorescence Validation of CX3CR1 in Rat Heart Tissue</strong><br> Immunofluorescent analysis of 4% paraformaldehyde-fixed rat heart tissue labeling CX3CR1 with 2093 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).
    • <strong>Figure 12 Immunofluorescence Validation of CX3CR1 in Human Atherosclerosis (Lucas et al., 2003)</strong><br> CX3CR1-positive cells in coronary artery sections was detected by anti-CX3CR1 antibodies by double staining with an anti–smooth muscle actin antibody (yellow).
    • <strong>Figure 13 Regulated Expression Validation of CX3CR1 in Mouse Bone Marrow-derived NK Cells (Barlic et al., 2003)</strong><br> Western blot analysis of CX3CR1 expression detected by anti-CX3CR1 antibodies was induced by IL-2 but was inhibited by IL-15. Mouse skeletal muscle was for negative control and mouse brain was for positive control.
    • <strong>Figure 14 Flow Cytometry Validation of CX3CR1 in Peripheral Blood Mononuclear Cells (PBMCs) of Patients (Yajima et al., 2005)</strong><br> Flow cytometry analysis of CX3CR1 expression detected by anti-CX3CR1 antibodies. Protein expression was more pronounced on CD4<sup>+</sup> and CD8<sup>+</sup> T cells from patients with untreated active systemic lupus erythematosus (SLE) as compared to those with rheumatoid arthritis (RA) or healthy controls.
    • <strong>Figure 15 CX3CR1 Deficiency Validation in Transgenic Mice (Kumar et al., 2013)</strong><br> Transgenic CX3CR1 gfp (C57BL6/J background) mice, in which either one (CX3CR1 gfp/+ ) or both (CX3CR1 gfp/gfp ) copies of the CX3CR1 gene were interrupted by fluorescent protein (GFP). More CX3CR1 positive cells (green) are found in vascular wall of CX3CR1 gfp/+ mice, but not in CX3CR1 gfp/gfp mice, where cells remained in perivascular region due to leaky microvessels. CX3CR1 expression was detected by anti-CX3CR1 antibodies.
Items 1 to 10 of 17 total
per page
Page:
  1. 1
  2. 2
Shop By
Currently Shopping by:
  1. Remove This Item Conjugate: Unconjugated
  2. Remove This Item Tested Applications: Func
  3. Remove This Item Tested Applications: IHC-P
  4. Remove This Item Species Reactivity: Rat
  5. Remove This Item Species Reactivity: HIV-1
  6. Remove This Item Species Reactivity: MRSA
Clear All
Refine by
Product type
  1. Primary Antibodies (17)
Conjugate
  1. Unconjugated (17)
Host Species
  1. Mouse (1)
  2. Rabbit (16)
Modifications
  1. None (17)
Tested Applications
  1. ELISA (29)
  2. Flow (3)
  3. Func (1)
  4. ICC (4)
  5. IF (20)
  6. IHC (1)
  7. IHC-P (17)
  8. IP (1)
  9. WB (31)
Show Less Show More
Species Reactivity
  1. HIV-1 (0)
  2. HPV-16 (3)
  3. Human (33)
  4. Mouse (21)
  5. MRSA (0)
  6. Rat (17)
  7. Virus (6)
Show Less Show More
Clonality
  1. Monoclonal (1)
  2. Polyclonal (16)

Research Area

Custom Antibody Services

Product Type

Support

About ProSci

Resources

Contact ProSci

  • 12170 Flint Place
    Poway, CA 92064, USA
  •  
  • Toll-Free: +1 (888) 513 9525
  • Phone: +1 (858) 513 2638
  • Fax: +1 (858) 513 2692
  • Email: info@prosci-inc.com

Follow Us:

  • ProSci Facebook
  • ProSci Twitter
  • ProSci LinkedIn

  • ProSci Newsletter
  • ProSci Research Gate